Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $7.7143.

A number of equities research analysts have recently issued reports on HUMA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. BTIG Research reissued a “buy” rating and set a $3.00 price objective on shares of Humacyte in a research report on Tuesday, April 28th. Wall Street Zen downgraded shares of Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 11th. Benchmark cut their price objective on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 21st. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Tuesday, April 28th.

Humacyte Trading Down 1.9%

Shares of HUMA stock opened at $1.06 on Friday. Humacyte has a 1 year low of $0.55 and a 1 year high of $2.93. The firm has a fifty day moving average price of $0.87 and a 200-day moving average price of $1.09. The company has a debt-to-equity ratio of 20.08, a current ratio of 3.69 and a quick ratio of 2.95. The company has a market cap of $235.34 million, a price-to-earnings ratio of -5.30 and a beta of 2.31.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%. The firm had revenue of $0.47 million during the quarter, compared to the consensus estimate of $1.35 million. As a group, equities analysts predict that Humacyte will post -0.39 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Wealth Effects LLC boosted its holdings in Humacyte by 33.6% in the 1st quarter. Wealth Effects LLC now owns 204,500 shares of the company’s stock worth $124,000 after buying an additional 51,433 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in Humacyte by 841.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company’s stock worth $68,000 after buying an additional 62,931 shares during the period. Aristides Capital LLC bought a new position in Humacyte in the 4th quarter worth $156,000. Fisher Asset Management LLC bought a new position in Humacyte in the 4th quarter worth $47,000. Finally, UBS Group AG boosted its holdings in Humacyte by 48.8% in the 4th quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock worth $2,862,000 after buying an additional 976,275 shares during the period. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.